Dose-escalated SBRT for borderline and locally advanced pancreatic cancer. Feasibility, safety and preliminary clinical results of a multicenter study
Background: Pancreatic Stereotactic Body Radiotherapy (SBRT) allows for the administration of a higher biologically effective doses (BED), that would be essential to achieve durable tumor control. Escalating treatment doses need a very accurate tumor positioning and motion control during radiotherap...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2024-03-01
|
| Series: | Clinical and Translational Radiation Oncology |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2405630824000302 |
| _version_ | 1827325498177355776 |
|---|---|
| author | B. Salas L. Ferrera-Alayón A. Espinosa-López A. Vera-Rosas E. Salcedo A. Kannemann A. Alayon R. Chicas-Sett M. LLoret P.C. Lara |
| author_facet | B. Salas L. Ferrera-Alayón A. Espinosa-López A. Vera-Rosas E. Salcedo A. Kannemann A. Alayon R. Chicas-Sett M. LLoret P.C. Lara |
| author_sort | B. Salas |
| collection | DOAJ |
| description | Background: Pancreatic Stereotactic Body Radiotherapy (SBRT) allows for the administration of a higher biologically effective doses (BED), that would be essential to achieve durable tumor control. Escalating treatment doses need a very accurate tumor positioning and motion control during radiotherapy.The aim of this study to assess the feasibility and safety of a Simultaneous Integrated Boost (SIB) dose-escalated protocol at 45 Gy, 50 Gy and 55 Gy in 5 consecutive daily fractions, in Border Line Resectable Pancreatic Cancer (BRCP) /Locally Advanced Pancreatic Cancer (LAPC) by means of a standard LINAC platform. Methods: Patients diagnosed of BRPC/LAPC, candidates for neoadjuvant chemotherapy and SBRT, in four university hospitals of the province of Las Palmas (Canary Islands, Spain) were included in this prospective study. Radiotherapy was administered using standard technology (LINACS) with advanced positioning (Lipiodol® and metallic stent used as fiducial markers) and tumor motion control (4D, DBH, Calypso®). There were 3 planned dose-escalated SIB groups, 45 Gy/5f (9 patients) 50 Gy/5f (9 + 9 patients) and 55 Gy/5f (9 patients). The defined primary end points of the study were the safety and feasibility of the proposed treatment protocol. Secondary endpoints included radiological tumor response after SBRT, local control and survival. Results: From June 2017 to December 2022, sixty-two patients were initially assessed for eligibility in the study in the four participating centers, and 49 were candidates for chemotherapy (CHT). Forty-one were referred to radiotherapy after CHT and 33 finally were treated by escalated-dose SIB, 45 Gy (9 patients) 50 Gy (16 patients), 55 Gy(8 patients). All patients completed the scheduled treatment and no acute or late severe (≥grade3) gastrointestinal toxicity was observed.Local response was analyzed by CT/MRI two months after the end of SBRT. Ten patients (31,25 %) achieved objective response (2/9:45 Gy, 5/15:50 Gy, 3/8:55 Gy). Follow-up was closed as July 2023. Freedom from local progression at 1-2y were 89,3% (95 %CI:83,4–95,2%) and 66 % (95 %CI:54,6–77,4%) respectively. The 1-2y survival rates were 95,7% (95 %CI:91,4–100 % and 48,6% (95 %CI:37,7–59,5%) respectively. Conclusion: These promising results should be confirmed by further studies with larger sample size and extended follow-up period. |
| first_indexed | 2024-03-07T14:29:07Z |
| format | Article |
| id | doaj.art-7c2492fd27db4a2cb7e31fc5c1037121 |
| institution | Directory Open Access Journal |
| issn | 2405-6308 |
| language | English |
| last_indexed | 2024-03-07T14:29:07Z |
| publishDate | 2024-03-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Clinical and Translational Radiation Oncology |
| spelling | doaj.art-7c2492fd27db4a2cb7e31fc5c10371212024-03-06T05:27:54ZengElsevierClinical and Translational Radiation Oncology2405-63082024-03-0145100753Dose-escalated SBRT for borderline and locally advanced pancreatic cancer. Feasibility, safety and preliminary clinical results of a multicenter studyB. Salas0L. Ferrera-Alayón1A. Espinosa-López2A. Vera-Rosas3E. Salcedo4A. Kannemann5A. Alayon6R. Chicas-Sett7M. LLoret8P.C. Lara9Department of Radiation Oncology University Hospital Dr Negrín Las Palmas de Gran Canaria, Barranco de la Ballena s/n, 35010 Las Palmas de Gran Canaria, SpainDepartment of Radiation Oncology University Hospital Dr Negrín Las Palmas de Gran Canaria, Barranco de la Ballena s/n, 35010 Las Palmas de Gran Canaria, Spain; Las Palmas de Gran Canaria University (ULPGC) ,C. Juan de Quesada, 30, 35001 Las Palmas de Gran Canaria,SpainDepartment of Radiation Oncology, University Hospital Virgen de la Arrixaca, Carretera Madrid-Cartagena, S/N, 30120 El Palmar (Murcia), SpainDepartment of Radiation Oncology University Hospital Dr Negrín Las Palmas de Gran Canaria, Barranco de la Ballena s/n, 35010 Las Palmas de Gran Canaria, SpainDepartment of Radiation Oncology University Hospital Dr Negrín Las Palmas de Gran Canaria, Barranco de la Ballena s/n, 35010 Las Palmas de Gran Canaria, SpainDepartment of Radiation Oncology University Hospital Dr Negrín Las Palmas de Gran Canaria, Barranco de la Ballena s/n, 35010 Las Palmas de Gran Canaria, SpainDepartment of Radiation Oncology University Hospital Dr Negrín Las Palmas de Gran Canaria, Barranco de la Ballena s/n, 35010 Las Palmas de Gran Canaria, SpainDepartment of Radiation Oncology, ASCIRES GRUPO BIOMEDICO, Valencia, SpainDepartment of Radiation Oncology University Hospital Dr Negrín Las Palmas de Gran Canaria, Barranco de la Ballena s/n, 35010 Las Palmas de Gran Canaria, Spain; Las Palmas de Gran Canaria University (ULPGC) ,C. Juan de Quesada, 30, 35001 Las Palmas de Gran Canaria,Spain; Instituto Canario de Investigacion del Cáncer ICICInstituto Canario de Investigacion del Cáncer ICIC; Canarian Comprehensive Cancer Center, Department of Oncology University Hospital San Roque, C. Dolores de la Rocha, 5, 35001 Las Palmas de Gran Canaria, Spain; Fernando Pessoa Canarias University, Calle la Juventud, s/n, 35450 Guía, Las Palmas de Gran Canaria, Spain; Corresponding author at: Canarian Comprehensive Cancer Center, San Roque University Hospital, Dolores de la Rocha 5, 35001 Las Palmas Gran Canaria, Spain.Background: Pancreatic Stereotactic Body Radiotherapy (SBRT) allows for the administration of a higher biologically effective doses (BED), that would be essential to achieve durable tumor control. Escalating treatment doses need a very accurate tumor positioning and motion control during radiotherapy.The aim of this study to assess the feasibility and safety of a Simultaneous Integrated Boost (SIB) dose-escalated protocol at 45 Gy, 50 Gy and 55 Gy in 5 consecutive daily fractions, in Border Line Resectable Pancreatic Cancer (BRCP) /Locally Advanced Pancreatic Cancer (LAPC) by means of a standard LINAC platform. Methods: Patients diagnosed of BRPC/LAPC, candidates for neoadjuvant chemotherapy and SBRT, in four university hospitals of the province of Las Palmas (Canary Islands, Spain) were included in this prospective study. Radiotherapy was administered using standard technology (LINACS) with advanced positioning (Lipiodol® and metallic stent used as fiducial markers) and tumor motion control (4D, DBH, Calypso®). There were 3 planned dose-escalated SIB groups, 45 Gy/5f (9 patients) 50 Gy/5f (9 + 9 patients) and 55 Gy/5f (9 patients). The defined primary end points of the study were the safety and feasibility of the proposed treatment protocol. Secondary endpoints included radiological tumor response after SBRT, local control and survival. Results: From June 2017 to December 2022, sixty-two patients were initially assessed for eligibility in the study in the four participating centers, and 49 were candidates for chemotherapy (CHT). Forty-one were referred to radiotherapy after CHT and 33 finally were treated by escalated-dose SIB, 45 Gy (9 patients) 50 Gy (16 patients), 55 Gy(8 patients). All patients completed the scheduled treatment and no acute or late severe (≥grade3) gastrointestinal toxicity was observed.Local response was analyzed by CT/MRI two months after the end of SBRT. Ten patients (31,25 %) achieved objective response (2/9:45 Gy, 5/15:50 Gy, 3/8:55 Gy). Follow-up was closed as July 2023. Freedom from local progression at 1-2y were 89,3% (95 %CI:83,4–95,2%) and 66 % (95 %CI:54,6–77,4%) respectively. The 1-2y survival rates were 95,7% (95 %CI:91,4–100 % and 48,6% (95 %CI:37,7–59,5%) respectively. Conclusion: These promising results should be confirmed by further studies with larger sample size and extended follow-up period.http://www.sciencedirect.com/science/article/pii/S2405630824000302LAPCBRPCsbrtSIBEscalated doseFeasibility |
| spellingShingle | B. Salas L. Ferrera-Alayón A. Espinosa-López A. Vera-Rosas E. Salcedo A. Kannemann A. Alayon R. Chicas-Sett M. LLoret P.C. Lara Dose-escalated SBRT for borderline and locally advanced pancreatic cancer. Feasibility, safety and preliminary clinical results of a multicenter study Clinical and Translational Radiation Oncology LAPC BRPC sbrt SIB Escalated dose Feasibility |
| title | Dose-escalated SBRT for borderline and locally advanced pancreatic cancer. Feasibility, safety and preliminary clinical results of a multicenter study |
| title_full | Dose-escalated SBRT for borderline and locally advanced pancreatic cancer. Feasibility, safety and preliminary clinical results of a multicenter study |
| title_fullStr | Dose-escalated SBRT for borderline and locally advanced pancreatic cancer. Feasibility, safety and preliminary clinical results of a multicenter study |
| title_full_unstemmed | Dose-escalated SBRT for borderline and locally advanced pancreatic cancer. Feasibility, safety and preliminary clinical results of a multicenter study |
| title_short | Dose-escalated SBRT for borderline and locally advanced pancreatic cancer. Feasibility, safety and preliminary clinical results of a multicenter study |
| title_sort | dose escalated sbrt for borderline and locally advanced pancreatic cancer feasibility safety and preliminary clinical results of a multicenter study |
| topic | LAPC BRPC sbrt SIB Escalated dose Feasibility |
| url | http://www.sciencedirect.com/science/article/pii/S2405630824000302 |
| work_keys_str_mv | AT bsalas doseescalatedsbrtforborderlineandlocallyadvancedpancreaticcancerfeasibilitysafetyandpreliminaryclinicalresultsofamulticenterstudy AT lferreraalayon doseescalatedsbrtforborderlineandlocallyadvancedpancreaticcancerfeasibilitysafetyandpreliminaryclinicalresultsofamulticenterstudy AT aespinosalopez doseescalatedsbrtforborderlineandlocallyadvancedpancreaticcancerfeasibilitysafetyandpreliminaryclinicalresultsofamulticenterstudy AT averarosas doseescalatedsbrtforborderlineandlocallyadvancedpancreaticcancerfeasibilitysafetyandpreliminaryclinicalresultsofamulticenterstudy AT esalcedo doseescalatedsbrtforborderlineandlocallyadvancedpancreaticcancerfeasibilitysafetyandpreliminaryclinicalresultsofamulticenterstudy AT akannemann doseescalatedsbrtforborderlineandlocallyadvancedpancreaticcancerfeasibilitysafetyandpreliminaryclinicalresultsofamulticenterstudy AT aalayon doseescalatedsbrtforborderlineandlocallyadvancedpancreaticcancerfeasibilitysafetyandpreliminaryclinicalresultsofamulticenterstudy AT rchicassett doseescalatedsbrtforborderlineandlocallyadvancedpancreaticcancerfeasibilitysafetyandpreliminaryclinicalresultsofamulticenterstudy AT mlloret doseescalatedsbrtforborderlineandlocallyadvancedpancreaticcancerfeasibilitysafetyandpreliminaryclinicalresultsofamulticenterstudy AT pclara doseescalatedsbrtforborderlineandlocallyadvancedpancreaticcancerfeasibilitysafetyandpreliminaryclinicalresultsofamulticenterstudy |